Recruiting
Phase 3

Denifanstat

Sponsor:

Sagimet Biosciences Inc.

Code:

NCT07863193

Conditions

Acne Vulgaris

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Denifanstat

Placebo

Study Details

Brief summary:

The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent to an open-label extension phase for an additional 40 weeks of treatment.

Conditions

Acne Vulgaris

Study ID

NCT07863193

Start date

Oct 21, 2026

Status verified date

Nov, 2026

Completion date

Apr, 2028

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Must be willing and able to participate in the trial and provide written informed consent or assent
2. Aged ≥12 years on the date that written informed consent/ assent is provided
3. Moderate to severe acne vulgaris based on the following criteria at screening:

1. The EGSS at screening of 3 or 4.

AND
2. Number of facial skin lesions:

  • 30 to 75 inflammatory lesions
  • 30 to 100 noninflammatory lesions
4. All participants with their partners, if any, must agree to the use of an acceptable method of highly effective contraception. Women of childbearing potential (WOCBP) must not be pregnant or breastfeeding, must not plan to become pregnant during the study, and must use 2 forms of birth control, one being a barrier method, or be sexually abstinent.

Exclusion Criteria:

1. Presence of >2 facial cysts/ nodules
2. Cystic acne, acne fulminans or acne conglobata
3. Other significant skin diseases that may affect the efficacy evaluation or require co-treatment
4. History of clinically significant dry eye, such as Ocular Surface Disease Index (OSDI) ≥33, or corneal staining ≥ grade III on Oxford Grading Scale, chronic dry eye, or other corneal abnormality
5. Use of concomitant strong cytochrome P450 (CYP) 3A4 inducers and strong or moderate inhibitors within 2 weeks prior to Day 1 the trial except Paxlovid®
6. Use of a glucagon-like-peptide 1 (GLP-1) agonist for <12 weeks prior to first dose of trial medication
7. Use of any of the following:

1. Introduction of any drug known to prolong QT interval corrected for heart rate (QTC)
2. Sensitive substrates of P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP)
3. Herbs and supplements such as St John's Wort or grapefruit juice.
8. Use of concomitant acne treatments unless appropriate washout period is documented

Study Design

Enrollment

800 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Denifanstat

placebo comparator: Placebo

Interventions

Denifanstat

Oral, once daily

Placebo

Oral, once daily

Primary outcome measure

  • Proportion of participants achieving EGSS success, defined as a score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from their baseline score [ Time Frame: Week 12 ]
  • Absolute change from baseline in inflammatory lesion count (ILC) [ Time Frame: Week 12 ]
  • Absolute change from baseline in non-inflammatory lesion count (ILC) [ Time Frame: Week 12 ]

Central Contacts and Locations

Central contacts

Locations

Sagimet Investigative Site

Recruiting

Bryant, Arkansas, United States, 72022

Sagimet Investigative Site

Recruiting

Beverly Hills, California, United States, 90211

Sagimet Investigative Site

Recruiting

Fremont, California, United States, 94538

Sagimet Investigative Site

Recruiting

San Diego, California, United States, 92123

Sagimet Investigative Site

Recruiting

Santa Ana, California, United States, 92705

Sagimet Investigative Site

Recruiting

Doral, Florida, United States, 33126

Sagimet Investigative Site

Recruiting

Fort Lauderdale, Florida, United States, 33308

Sagimet Investigative Site

Recruiting

Miami, Florida, United States, 33125

Sagimet Investigative Site

Recruiting

Miami, Florida, United States, 33126

Sagimet Investigative Site

Recruiting

Miami, Florida, United States, 33155

Sagimet Investigative Site

Recruiting

Miami, Florida, United States, 33175

Sagimet Investigative Site

Recruiting

Miramar, Florida, United States, 33027

Sagimet Investigative Site

Recruiting

Sweetwater, Florida, United States, 33182

Sagimet Investigative Site

Recruiting

Lincolnshire, Illinois, United States, 60069

Sagimet Investigative Site

Recruiting

Indianapolis, Indiana, United States, 46250

Sagimet Investigative Site

Recruiting

New Albany, Indiana, United States, 47150

Sagimet Investigative Site

Recruiting

Plainfield, Indiana, United States, 46168

Sagimet Investigative Site

Recruiting

Brighton, Massachusetts, United States, 02135

Sagimet Investigative Site

Recruiting

Ann Arbor, Michigan, United States, 48103

Sagimet Investigative Site

Recruiting

Clinton Township, Michigan, United States, 48038

Sagimet Investigative Site

Recruiting

Saint Joseph, Missouri, United States, 64506

Sagimet Investigative Site

Recruiting

Omaha, Nebraska, United States, 68144

Sagimet Investigative Site

Recruiting

Portsmouth, New Hampshire, United States, 03801

Sagimet Investigative Site

Recruiting

Robbinsville, New Jersey, United States, 08691

Sagimet Investigative Site

Recruiting

Wilmington, North Carolina, United States, 28045

Sagimet Investigative Site

Recruiting

Columbus, Ohio, United States, 43215

Sagimet Investigative Site

Recruiting

East Greenwich, Rhode Island, United States, 02818

Sagimet Investigative Site

Recruiting

Greenville, South Carolina, United States, 29615

Sagimet Investigative Site

Recruiting

Murfreesboro, Tennessee, United States, 37130

Sagimet Investigative Site

Recruiting

Nashville, Tennessee, United States, 37215

Sagimet Investigative Site

Recruiting

College Station, Texas, United States, 77845

Sagimet Investigative Site

Recruiting

El Paso, Texas, United States, 79902

Sagimet Investigative Site

Recruiting

Houston, Texas, United States, 77055

Sagimet Investigative Site

Recruiting

San Antonio, Texas, United States, 78215

Sagimet Investigative Site

Recruiting

Spokane, Washington, United States, 99202

More Information

Sponsor

Sagimet Biosciences Inc.

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-22. This information was provided to ClinicalTrials.gov by Sagimet Biosciences Inc. on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.